• GlucoTrack received a USPTO Notice of Allowance for a patent application covering its fully implantable continuous blood glucose monitoring platform.
• Allowed claims target an intravascular sensing lead linked to an electronics assembly, supporting long-term glucose monitoring in the vasculature.
• The filing builds on three CBGM patents issued in late 2025, extending protection around the platform’s sensor architecture.
• The system is designed for up to three years of monitoring with no wearable component, measuring glucose directly from blood to reduce lag.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080800PRIMZONEFULLFEED9758633) on July 08, 2026, and is solely responsible for the information contained therein.